N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Mitchell, M.L., Son, J.C., Guo, H., Im, Y.A., Cho, E.J., Wang, J., Hayes, J., Wang, M., Paul, A., Lansdon, E.B., Chen, J.M., Graupe, D., Rhodes, G., He, G.X., Geleziunas, R., Xu, L., Kim, C.U.(2010) Bioorg Med Chem Lett 20: 1589-1592
- PubMed: 20138513 
- DOI: https://doi.org/10.1016/j.bmcl.2010.01.085
- Primary Citation of Related Structures:  
3LAL, 3LAM, 3LAN - PubMed Abstract: 
A series of N1-alkyl pyrimidinediones were designed, synthesized and evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Our efforts identified compound 10b, which represents the lead compound in this series with pharmacokinetics and antiviral potency that may support once-daily dosing.
Organizational Affiliation: 
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA. mmitchell@gilead.com